$TCRT
Alaunos Therapeutics, Inc.

2016 Q4 Form 10-Q Financial Statement

#000119312516764305 Filed on November 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $1.600M $1.600M $1.870M
YoY Change -16.67% -14.44% 196.83%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.320M $3.540M $3.070M
YoY Change 1.84% 15.31% 8.1%
% of Gross Profit
Research & Development $9.390M $8.975M $16.97M
YoY Change 15.36% -47.11% 74.36%
% of Gross Profit
Depreciation & Amortization $60.00K $70.00K $60.00K
YoY Change 0.0% 16.67% -50.0%
% of Gross Profit
Operating Expenses $12.71M $8.975M $16.97M
YoY Change 11.49% -47.11% 74.36%
Operating Profit -$11.11M -$10.91M -$18.17M
YoY Change 17.18% -39.92% 52.12%
Interest Expense -$150.0K $20.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $30.00K $39.00K -$4.000K
YoY Change 200.0% -1075.0% -300.0%
Pretax Income -$11.22M -$10.85M -$18.17M
YoY Change 18.35% -40.29% 198.36%
Income Tax
% Of Pretax Income
Net Earnings -$14.76M -$14.45M -$18.17M
YoY Change 55.72% -20.5% 198.21%
Net Earnings / Revenue -922.25% -902.81% -971.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.11 -$0.11 -$0.14
COMMON SHARES
Basic Shares Outstanding 131.7M shares 131.7M shares 130.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $81.10M $94.70M $163.8M
YoY Change -42.36% -42.19% 255.31%
Cash & Equivalents $81.05M $94.68M $163.8M
Short-Term Investments
Other Short-Term Assets $23.80M $21.00M $8.300M
YoY Change 108.77% 153.01% 453.33%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $104.9M $115.7M $172.5M
YoY Change -31.23% -32.93% 260.73%
LONG-TERM ASSETS
Property, Plant & Equipment $843.0K $825.0K $262.0K
YoY Change 45.09% 214.89% -59.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $493.0K $492.0K $491.0K
YoY Change -0.2% 0.2% -4.29%
Total Long-Term Assets $1.464M $1.445M $881.0K
YoY Change 21.7% 64.02% -31.97%
TOTAL ASSETS
Total Short-Term Assets $104.9M $115.7M $172.5M
Total Long-Term Assets $1.464M $1.445M $881.0K
Total Assets $106.3M $117.1M $173.4M
YoY Change -30.82% -32.44% 253.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $156.0K $1.814M $4.154M
YoY Change -92.23% -56.33% 112.7%
Accrued Expenses $9.109M $7.364M $18.14M
YoY Change 2.28% -59.4% 132.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.81M $15.74M $29.63M
YoY Change -12.77% -46.86% 153.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $42.50M $44.00M $49.90M
YoY Change -11.83% -11.82% 249400.0%
Total Long-Term Liabilities $42.50M $44.00M $49.90M
YoY Change -11.83% -11.82% 249400.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.81M $15.74M $29.63M
Total Long-Term Liabilities $42.50M $44.00M $49.90M
Total Liabilities $58.33M $59.73M $79.52M
YoY Change -12.1% -24.89% 529.51%
SHAREHOLDERS EQUITY
Retained Earnings -$658.0M -$646.8M -$483.2M
YoY Change 33.55% 33.85% 33.41%
Common Stock $580.7M $582.4M $577.1M
YoY Change 0.11% 0.92% 44.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$77.30M -$64.42M $93.84M
YoY Change
Total Liabilities & Shareholders Equity $106.3M $117.1M $173.4M
YoY Change -30.82% -32.44% 253.01%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$14.76M -$14.45M -$18.17M
YoY Change 55.72% -20.5% 198.21%
Depreciation, Depletion And Amortization $60.00K $70.00K $60.00K
YoY Change 0.0% 16.67% -50.0%
Cash From Operating Activities -$13.07M -$14.11M $45.20M
YoY Change -45.08% -131.22% -530.89%
INVESTING ACTIVITIES
Capital Expenditures $80.00K $210.0K $10.00K
YoY Change -78.95% 2000.0% -88.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$80.00K -$210.0K -$10.00K
YoY Change -78.95% 2000.0% -88.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -490.0K 0.000 90.00K
YoY Change -145.79% -100.0% -97.57%
NET CHANGE
Cash From Operating Activities -13.07M -14.11M 45.20M
Cash From Investing Activities -80.00K -210.0K -10.00K
Cash From Financing Activities -490.0K 0.000 90.00K
Net Change In Cash -13.64M -14.32M 45.28M
YoY Change -40.98% -131.63% -758.14%
FREE CASH FLOW
Cash From Operating Activities -$13.07M -$14.11M $45.20M
Capital Expenditures $80.00K $210.0K $10.00K
Free Cash Flow -$13.15M -$14.32M $45.19M
YoY Change -45.62% -131.69% -527.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131732423 shares
CY2016Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
694000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163843000
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131732423 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2632629 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3357976 shares
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131732423 shares
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2317935 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.25
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3448070 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.08
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.25
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-646773000
CY2016Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
340000
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1814000
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3755000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94683000
CY2016Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2016Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
25000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4206000
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q3 us-gaap Liabilities
Liabilities
59726000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117122000
CY2016Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
694000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
-64416000
CY2016Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
694000
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
43125000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
132000
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
582225000
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
163000
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15744000
CY2016Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
177000
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7364000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
115677000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
825000
CY2016Q3 us-gaap Assets
Assets
117122000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
492000
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20969000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4319000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42803000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131718579 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131718579 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2120834 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.24
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3481469 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.96
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-492700000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Liabilities
Liabilities
66353000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153724000
CY2015Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
661000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18123000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
348000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6861000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2008000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
87371000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
47917000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
579939000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
313000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8906000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
152521000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
581000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8622000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140717000
CY2015Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2015Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
446000
CY2015Q4 us-gaap Assets
Assets
153724000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
494000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11358000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4782838 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
23792000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8170 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8001 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0166 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.10
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
123911796 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0193 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
254800 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
34000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Contracts Revenue
ContractsRevenue
2413000
us-gaap Operating Income Loss
OperatingIncomeLoss
-110618000
us-gaap Net Income Loss
NetIncomeLoss
-110612000
us-gaap Interest Paid
InterestPaid
0
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
379000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-110612000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7129000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Type
DocumentType
10-Q
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
224000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2150000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-69000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
67285000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-25000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94320000
us-gaap Share Based Compensation
ShareBasedCompensation
6054000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
295000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
55087000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14388000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10956000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
97273000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
581000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
113031000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98643000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
121040000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3366000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27249143 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-45261000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7934 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M7D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.81
dei Trading Symbol
TradingSymbol
ZIOP
dei Amendment Flag
AmendmentFlag
false
us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7926 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0127 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M26D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
21699 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.36
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.18
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.76
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130347370 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
157300 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0137 pure
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
169000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.21
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
157300 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y6M26D
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
469000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
21000
us-gaap Contracts Revenue
ContractsRevenue
5264000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
87000
us-gaap Operating Income Loss
OperatingIncomeLoss
-154196000
us-gaap Net Income Loss
NetIncomeLoss
-154073000
us-gaap Interest Paid
InterestPaid
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6094000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
853000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
551000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-157664000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9611000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-421000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-322000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-469000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3591000
us-gaap Share Based Compensation
ShareBasedCompensation
6094000
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
2000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
227000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
3591000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5264000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
109000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11058000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1542000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-304000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
231000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
159460000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
148402000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-46034000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
551000
ziop Issuance Of Common Stock In Connection With License Agreement
IssuanceOfCommonStockInConnectionWithLicenseAgreement
87000
ziop Change In Research And Development Expenses
ChangeInResearchAndDevelopmentExpenses
2700000
ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
3800000
ziop Research And Development Service Agreement Aggregate Payment
ResearchAndDevelopmentServiceAgreementAggregatePayment
22500000
ziop Restricted Stock Buy Back At Vesting To Cover Taxes Value
RestrictedStockBuyBackAtVestingToCoverTaxesValue
853000
ziop Issuance Of Preferred Stock In Connection With License Agreement
IssuanceOfPreferredStockInConnectionWithLicenseAgreement
118936000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M2D
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.71
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130496035 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
21300 shares
CY2016Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
21000
CY2016Q3 us-gaap Contracts Revenue
ContractsRevenue
1598000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10914000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-10854000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14445000
CY2016Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3591000
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2019000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3537000
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
109000
CY2016Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12512000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8975000
CY2016Q3 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
21000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.49
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
129732356 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
203000 shares
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
1869000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18166000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-18170000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18170000
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1477000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3065000
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
104000
CY2015Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
20035000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16970000

Files In Submission

Name View Source Status
0001193125-16-764305-index-headers.html Edgar Link pending
0001193125-16-764305-index.html Edgar Link pending
0001193125-16-764305.txt Edgar Link pending
0001193125-16-764305-xbrl.zip Edgar Link pending
d247257d10q.htm Edgar Link pending
d247257dex311.htm Edgar Link pending
d247257dex312.htm Edgar Link pending
d247257dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g247257snap2.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20160930.xml Edgar Link completed
ziop-20160930.xsd Edgar Link pending
ziop-20160930_cal.xml Edgar Link unprocessable
ziop-20160930_def.xml Edgar Link unprocessable
ziop-20160930_lab.xml Edgar Link unprocessable
ziop-20160930_pre.xml Edgar Link unprocessable